The Addition of Chloroquine to Chemoradiation for Glioblastoma

Condition(s) targeted: Glioblastoma Multiforme

Intervention: Chloroquine (Drug); Radiotherapy (Radiation); Temozolomide (Drug)

Phase: Phase 1

Status: Not yet recruiting

Sponsored by: Maastricht Radiation Oncology

Official(s) and/or principal investigator(s):
Philippe Lambin, prof., Principal Investigator, Affiliation: Maastro Clinic, The Netherlands

Overall contact:
Inge Compter, MD, Phone: +31 88 4455666, Email: Inge.Compter@maastro.nl

Patients with a glioblastoma (GBM) have a poor prognosis with a median survival of 14. 6 months after maximal treatment with a resection and chemoradiation. Since the pivotal trial evaluating the effect of temozolomide (TMZ), overall survival has not increased. Treatment of GBM xenografts in vivo with chloroquine (CQ), an antimalarial agent, has been shown to reduce the hypoxic fraction and sensitizes tumors to radiation. Epidermal growth factor receptor (EGFR) amplification or mutation is regularly observed GBM and is thought to be a major contributor to radioresistance. The most common EGFR mutation in GBM (EGFRvIII) is present in 50-60% of patients whose tumor shows amplification of EGFR. EGFR provides cells with a survival advantage through autophagy when exposed to stresses such as hypoxia and nutrient starvation. This effect is even more pronounced in EGFRvIII overexpressing tumors. Previously, the potential effect CQ has been demonstrated in a small randomized controlled trial in GBM treated with radiotherapy and carmustine, which showed a trend towards increased overall survival. However, as the intracellular effects of chloroquine are dose-dependent the maximum tolerated dose for CQ in combination with concurrent radiotherapy with daily temozolomide needs to be established.

Official title: A Phase I Trial for the Addition of Chloroquine, an Autophagy Inhibitor, in Combination With Concurrent Chemoradiation for Newly Diagnosed Glioblastoma

Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Toxicity (CTC AE 4.0

Secondary outcome:

Pharmacokinetics of chloroquine, desethylchloroquine, bisdesethylchloroquine. Profile parameters will include trough level (Cmin), AUC and elimination half-life.

Presence of autophagic markers (LC3 and autophagic vesicles)

Evaluation of EGFRvIII status in histopathological material

Detailed description: This trial has been designed as an open label, single center combination phase I trial. The primary objective is to determine the maximum tolerated dose (MTD) for chloroquine (CQ) in combination with concurrent radiotherapy with daily temozolomide in patients with a newly diagnosed GBM. Eligible patients will receive radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 33 daily fractions of 1. 8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² per os daily (po qd) and six adjuvant

cycles of TMZ 150 - 200 mg/m² po qd. Treatment will be combined with daily intake of

escalating doses of chloroquine. Chloroquine will start with week before the start of radiotherapy and end on the last day of radiotherapy. The rate of subject entry and escalation to the next dose level will depend upon assessment of the safety profile of patients entered at the previous dose level. Toxicity will be evaluated according to the NCI common Terminology Criteria for Adverse Events (CTCAE), Version 4. 0. The 3 + 3 cohort method is used. A minimum of three patients will be entered at each dose level. All three will be followed during the concomitant radiotherapy and a 4 week observation period before escalation to the next dose level. The start dose is 200mg chloroquine daily. Before opening the next higher dose level all toxic effects at the preceding dose level will be reviewed and expansion or escalation will be undertaken as appropriate

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Histologically confirmed grade IV supratentorial astrocytoma (glioblastoma

multiforme)

- Tumor tissue available for histopathological analysis (MGMT, EGFRvIII)

- Diagnosis must have been made by biopsy or resection ≤ 3 months prior to study entry

- 18 years or older

- WHO performance status 0-2

- Absolute neutrophil count at least 1. 5 x 109/L and platelets at least 100 x109/L

- Adequate renal function

- Adequate hepatic function

- absence of any psychological, familial, sociological or geographical condition

potentially hampering compliance with the study protocol and follow-up schedule.

- Females must have negative results for pregnancy tests performed

- No breast feeding.

- If male, subject must be surgically sterile or practicing a method of contraception

Exclusion Criteria:

- Prior radiotherapy

- Prior chemotherapy

- Pregnancy or breast feeding

- Recent (< 3 months) severe cardiac disease (NYHA class >1) (congestive heart failure,

infarction)

- History of cardiac arrythmia (multifocal premature ventricular contractions,

uncontrolled atrial fibrillation, bigeminy, trigeminy, ventricular tachycardia) which is symptomatic and requiring treatment (CTC AE 4. 0), or asymptomatic sustained ventricular tachycardia. Asymptomatic atrial fibrillation controlled on medication is allowed.

- Cardiac conduction disturbances or medication potentially causing them

- Treatment with investigational drugs in 4 weeks prior to or during this study

- If the subject has clinically significant and uncontrolled major medical condition(s)

including but not limited to:

- uncontrolled nausea/vomiting/diarrhea:

- active uncontrolled infection, including HIV and hepatitis (HBV, HCV)

- psychiatric illness/social situation that would limit compliance with study

requirements

- any medical condition, with the opinion of the study investigator, places the

subject at an unacceptably high risk for toxicities.

- The subject has had another active malignancy within the past 3 years except for any

cancer in situ that the principal Investigator considers to be cured.

- Chronic systemic immune therapy (with the exception of corticosteroids)

- Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs (e. g., phenytoin,

carbamazepine, phenobarbital, primidone, or oxcarbazepine)

- Known glucose-6-phosphate dehydrogenase deficiency

- Psoriasis or porphyria

- Known hypersensitivity to 4-aminoquinoline compound

- Retinal or visual field changes unrelated to the tumor location prior to

4-aminoquinoline compound use

Inge Compter, MD, Phone: +31 88 4455666, Email: Inge.Compter@maastro.nl

Related publications:

Jutten B, Rouschop KM. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Cell Cycle. 2014;13(1):42-51. doi: 10.4161/cc.27518. Epub 2013 Dec 13. Review.

Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, Keulers T, Mujcic H, Landuyt W, Voncken JW, Lambin P, van der Kogel AJ, Koritzinsky M, Wouters BG. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest. 2010 Jan;120(1):127-41. doi: 10.1172/JCI40027. Epub 2009 Dec 14.

Starting date: August 2015
Last updated: February 27, 2015